Get the Stockscreener App
2.05
4.21%
-0.09
After Hours:
2.05
Compugen Ltd stock is traded at $2.05, with a volume of 206.40K.
It is down -4.21% in the last 24 hours and up +28.93% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$2.14
Open:
$2.13
24h Volume:
206.40K
Relative Volume:
0.49
Market Cap:
$191.75M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
68.33
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
+14.53%
1M Performance:
+28.93%
6M Performance:
+43.36%
1Y Performance:
+13.26%
1-Day Range:
$2.005
$2.135
1-Week Range:
$1.74
$2.31
52-Week Range:
$1.13
$2.38
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.05 | 200.17M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - AOL.com
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative - simplywall.st
Compugen (CGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compugen earnings beat by $0.68, revenue topped estimates - Investing.com South Africa
Chegg Earnings: Big Quarter Sends Shares Higher - AOL.com
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compugen Q4 2025 Earnings Call Transcript - MarketBeat
Compugen Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
What Smart Money Loves About Lilly - AOL.com
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Earnings call transcript: Compugen Q4 2025 sees earnings beat, stock surges - Investing.com Nigeria
CGEN: 2025 saw a cash runway extension, profitability, and global clinical trial progress - TradingView
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CGEN: 2025 saw strong revenue growth, a return to profitability, and extended cash runway into 2029 - TradingView
Compugen: Overview of Fourth Quarter Financial Results - Bitget
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress - TipRanks
Partnership payments lift Compugen (NASDAQ: CGEN) to 2025 profit - Stock Titan
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen stock jumps 5% on fourth quarter earnings beat - Investing.com
Compugen: Q4 Earnings Snapshot - marketscreener.com
Compugen : Corporate Presentation - marketscreener.com
Earnings Breakdown: Compugen Q4 - Benzinga
CGEN: Profitability achieved in 2025, driven by AstraZeneca deal and robust clinical progress - TradingView
Compugen (Nasdaq: CGEN) swings to 2025 profit, extends cash runway to 2029 - Stock Titan
Compugen Reports Fourth Quarter and Full Year 2025 Results - Yahoo Finance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Uncovering Potential: Compugen's Earnings Preview - Benzinga
Compugen Ltd expected to post earnings of 5 cents a shareEarnings Preview - TradingView
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition - AOL.com
Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
MSN Money - MSN
Compugen CEO Highlights COM701 Ovarian Cancer MAIA Trial, AstraZeneca and Gilead Updates at Oppenheimer Conf - Defense World
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% - AOL.com
Compugen at Oppenheimer Conference: Strategic Insights on Partnerships - Investing.com India
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Compass Stock a Buy After Kanen Added 1.6 Million Shares to Its Position? - AOL.com
Analyzing Sana Biotechnology (NASDAQ:SANA) & Compugen (NASDAQ:CGEN) - Defense World
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - AOL.com
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):